Molecular Partners AG (MOLN)
NASDAQ: MOLN · Real-Time Price · USD
5.20
-0.21 (-3.88%)
Nov 20, 2024, 4:00 PM EST - Market closed
Molecular Partners AG Employees
Molecular Partners AG had 168 employees as of December 31, 2023. The number of employees decreased by 8 or -4.45% compared to the previous year.
Employees
168
Change (1Y)
-8
Growth (1Y)
-4.45%
Revenue / Employee
$42,420
Profits / Employee
-$442,374
Market Cap
199.84M
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
Amarin Corporation | 275 |
Editas Medicine | 265 |
Inhibrx Biosciences | 172 |
Quantum-Si incorporated | 159 |
Solid Biosciences | 88 |
XBiotech | 82 |
Acrivon Therapeutics | 61 |
Lexeo Therapeutics | 58 |
MOLN News
- 13 days ago - Molecular Partners Presents Preclinical Proof-of-Concept for CD3 Switch-DARPin T Cell Engager, Clinical Biomarker Analyses for MP0317 at SITC 2024 - GlobeNewsWire
- 20 days ago - Molecular Partners Q3 2024 Interim Management Statement: Multiple Updates Across Portfolio, Radio-DARPin candidate MP0712 preparing for clinical entry, MP0533 Phase 1 on-going - GlobeNewsWire
- 27 days ago - Molecular Partners Announces Pricing of $20 Million Underwritten Offering - GlobeNewsWire
- 4 weeks ago - Molecular Partners and Orano Med Present Additional Positive Preclinical Data Supporting DLL3 Targeting Radio-DARPin Therapeutic Candidate MP0712 at EANM 2024 - GlobeNewsWire
- 4 weeks ago - Molecular Partners and Orano Med Strengthen Agreement to Co-Develop 212Pb-Based Radio-DARPin Therapeutics - GlobeNewsWire
- 6 weeks ago - Molecular Partners Announces upcoming poster presentations at the 2024 SITC Annual Meeting - GlobeNewsWire
- 7 weeks ago - Molecular Partners Announces Upcoming Top-Rated Oral Presentation on MP0712, a ²¹²Pb-labeled Radio-DARPin Therapeutic targeting DLL3 for Small Cell Lung Cancer co-developed with Orano Med, at EANM 2024 - GlobeNewsWire
- 3 months ago - Molecular Partners Reports H1 2024 Corporate Highlights and Financials - GlobeNewsWire